With the recent progress in reduced-intensity conditioning stem cell transplantation (RIST) and taking into consideration the concept of feto-maternal immunological tolerance, we carried out non-T-cell depleted HLA haploidentical RIST from noninherited maternal antigen (NIMA) complementary siblings or offspring donors for four older patients: a patient with myeloplastic syndrome (MDS) and three patients with adult T-cell leukemia (ATL) in partial remission or with progressive disease. All patients showed early, durable engraftment, and no serious toxicities were observed apart from grade III mucositis in one case. Grade II acute GVHD occurred in two cases, which was wellcontrolled. In one ATL patient whose donor did not have NIMA microchimerism, tacrolimus could not be continued after engraftment due to renal dysfunction, and grade III acute GVHD (gut: stage 4) occurred on day 35. A patient with MDS was free from disease (requiring no transfusions and with a normal bone marrow) for 15 months. Two cases of ATL relapsed. Feto-maternal tolerance may lead to new RIST strategies in the haploidentical reduced-intensity situation, but further evaluation is required. suggest an attractive strategy to bypass the lack of suitable donors. Based on the hypothesis of feto-maternal immunological tolerance, favorable results of non-T-cell depleted haploidentical SCT from a noninherited maternal antigen (NIMA) complementary sibling have been reported. With the progress in RIST and taking into consideration the concept of feto-maternal tolerance, we describe the results of reduced-intensity non-T-cell depleted HLA haploidentical SCT for older patients.
noninherited maternal antigen; feto-maternal tolerance Recent progress in reduced-intensity stem cell transplantation (RIST) has expanded the use of stem cell transplantation (SCT) to older patients and patients with various underlying diseases, 1 although there are still many patients without matched donors. Haploidentical donors are available for the majority of patients, but the previously reported results of haploidentical SCT are not acceptable due to severe graft versus host disease (GVHD) 2 and an increase in graft failure, especially in T-cell depleted SCT. 3 The recently reported favorable results of haploidentical SCT based on feto-maternal microchimerism 4 suggest an attractive strategy to bypass the lack of suitable donors. Based on the hypothesis of feto-maternal immunological tolerance, favorable results of non-T-cell depleted haploidentical SCT from a noninherited maternal antigen (NIMA) complementary sibling have been reported. With the progress in RIST and taking into consideration the concept of feto-maternal tolerance, we describe the results of reduced-intensity non-T-cell depleted HLA haploidentical SCT for older patients.
Patients and methods

Patients and donors
From January 2003 to January 2004, four older patients underwent HLA haploidentical SCT after agreement from the hospital ethics committee, and written informed consent had been given by the patients. None of the patients had suitable related or unrelated donors. Therefore, based on the hypothesis of feto-maternal tolerance, NIMA complementary siblings or offspring were selected as haploidentical donors. Feto-maternal microchimerism was examined by nested polymerase chain reaction with sequence-specific primer typing according to a previous report. 4 However, patient eligibility did not depend on the results of microchimerism.
Preparative regimen, graft-versus-host disease (GVHD) prophylaxis, and supportive care
The conditioning regimen included fludarabine at a daily dose of 30 mg/m 2 on days À8 to À3 (total dose 180 mg/m 2 ) and busulfan at a daily dose of 4 mg/kg on days À6 and À5 (total dose 8 mg/kg). Because of the limited evidence for maternal tolerance to an offspring and the aggressive nature of the disease, the patients with ATL with offspring donors received additional total-body irradiation (4 Gy) on day À7. Thereafter, patients received unmanipulated G-CSF-mobilized peripheral blood stem cells. As GVHD prophylaxis tacrolimus was initially administered from day À1 at a dose of 0.02 mg/kg/day as a continuous infusion, and short-course methotrexate was administered on days 1, 3, and 5 at doses of 10, 7, and 7 mg/m 2 . All patients were screened weekly for cytomegalovirus (CMV) viremia by a direct immunoperoxidase technique using a peroxidase-labeled monoclonal antibody (HRP-C7) against CMV immediate early antigen; 5 they were treated with ganciclovir if CMV viremia was detected.
Results
Patients and disease status at the time of transplantation
Four older patients ranging from 51 to 62 years of age underwent SCT ( Table 1 ). The first patient was a 61-yearold woman with myelodysplastic syndrome (MDS), refractory anemia with ringed sideroblasts (RARS) which had been diagnosed in 1997. She had received a total of 42 red cell transfusions before the SCT, and her transfusion requirements were increasing. The second patient was a 62-year-old woman with acute type refractory adult T-cell leukemia (ATL) diagnosed in August 2002. She had undergone reduced-intensity cord blood SCT in May 2003, but the graft had been rejected. The third patient was a 59-year-old woman with acute type refractory ATL diagnosed in January 2003 which prior intensive treatment had failed to control. Because of poor renal function due to previous chemotherapy and treatment of CMV infection, the fludarabine dose was modified. The fourth patient was a 51-year-old woman with acute ATL diagnosed in September 2003. Relapse was observed during CHOP treatment. Thus, three high risk patients with ATL were included in this study. Disease status at the time of transplantation for ATL was partial remission or progressive disease with hypercalcemia (Table 1 ). All patients and donors were seropositive for CMV.
HLA compatibilities and microchimerism
Various patterns of HLA diversity were observed between patients and donors ( Table 2 ). Microchimerism of recipient HLA was demonstrated in the peripheral blood of three of four donors.
Engraftment and early toxicities
Total numbers of CD34 þ cells infused are shown in Table 3 . Although patients had two or three mismatched HLA loci in the host versus graft direction, all showed early engraftment. Severe early toxicities were not observed with the exception of grade III mucositis 6 in case 3. Complete donor T-cell chimerism was confirmed by day 30 in cases 1-3. In case 4, mixed chimerism remained, due to residual ATL.
GVHD, late complications and survival
Acute GVHD occurred in three of the four cases as shown in Table 3 , and was well-controlled in cases 1 and 2. In case 3, whose donor did not have NIMA microchimerism in his peripheral blood, tacrolimus could not be continued after engraftment due to renal dysfunction, and stage 4 gut GVHD occurred on day 35. Methylprednisolone at a dose of 10 mg/kg/day was initiated, but did not control the problem. CMV-viremia was detected in all cases and CMV esophagitis occurred in case 2 on day 64.
Case 1 (MDS/RARS) was disease-free (no transfusions and normal bone marrow findings) for 437 days of followup with extensive chronic GVHD. The CD4 þ lymphocyte count and serum IgG level recovered to normal 7 months after transplantation. Relapse of ATL was observed in case 2 on day 74 but spontaneously resolved following withdrawal of tacrolimus and the re-emergence of skin GVHD. However, relapse occurred in the central nervous system on day 120, and she died of disease on day 134. Case 3 died of gut GVHD on day 58. In case 4, tacrolimus was stopped on day 22 because residual leukemia cells were detected in the peripheral blood. A donor leukocyte infusion was given on day 38; however, further chemotherapy was needed to control the ATL.
Discussion
The effect of tolerance to NIMA on transplantation was first demonstrated in the field of renal transplantation. 7 With this in mind, retrospective analysis of Japanese nationwide surveys for adult conventional SCT demonstrated a higher overall survival in patients receiving maternal hematopoietic stem cell (HSC) compared with those receiving paternal HSC. 8 A retrospective analysis by the International Bone Marrow Transplantation Registry (IBMTR) revealed the effect of tolerance to NIMA on occurrence of GVHD in the setting of conventional transplantation. 9 Although the duration of follow-up is too short for reliable evaluation in the setting of an aggressive disease, favorable engraftment and control of GVHD were observed in our study. In RIST for older patients, their siblings are in a similar age group and often have health problems which prevent them from providing stem cells. Our results in haploidentical SCT from offspring to mother are encouraging, making RIST feasible for older patients without appropriate donors. Patient 3, whose donor did not have NIMA microchimerism in his peripheral blood, developed severe gut GVHD. However, this severe GVHD was most likely related to the cessation of tacrolimus because of renal dysfunction. The significance of fetomaternal microchimerism as an index for feto-maternal tolerance needs to be evaluated.
Despite the frequent detection of feto-maternal microchimerism, 10 the results in renal transplantation, 7 and the retrospective analysis of conventional SCT 8, 9 all of which strongly support the concept of feto-maternal tolerance, immunological and clinical evidence has been limited. Furthermore, long-term problems, such as slow immune reconstitution in mismatched SCT 11 and lateonset GVHD in RIST 12 may influence outcome, especially in older patients. Further evaluation is needed to clarify this concept. However, feto-maternal immunological tolerance might lead to new SCT strategies with reducedintensity conditioning for older patients without a matched donor. aGVHD ¼ acute graft versus host disease; N ¼ day of neutrophil engraftment (40.5 Â 10 9 /l); P ¼ day of platelet engraftment (450 Â 10 9 /l); * ¼ never fell below 0.5 Â 10 9 /l; CR ¼ complete remission (free from transfusion with normal findings of bone marrow).
